

# 1 **Epidemiological surveillance of respiratory pathogens in wastewater in** 2 **Belgium**

3 Annabel Rector<sup>1</sup>, Mandy Bloemen<sup>1</sup>, Marijn Thijssen<sup>1</sup>, Bram Pussig<sup>2</sup>, Kurt Beuselinck<sup>3</sup>, Marc  
4 Van Ranst<sup>1,3</sup> and Elke Wollants<sup>1\*</sup>

5

6 <sup>1</sup>KU Leuven, Rega Institute, Department of Microbiology, Immunology and Transplantation,  
7 Laboratory of Clinical and Epidemiological Virology, 3000 Leuven, Belgium.

8 <sup>2</sup>KU Leuven, Department of Public health and Primary Care, Academic Center for General Practice,  
9 Leuven, Belgium

10 <sup>3</sup>University Hospitals Leuven, Department of Laboratory Medicine, National Reference Center for  
11 Respiratory Pathogens, 3000 Leuven, Belgium.

12

13 \*Corresponding author: [elke.wollants@kuleuven.be](mailto:elke.wollants@kuleuven.be) ; +32 16 32 13 41; Herestraat 49 box 1040,  
14 BE3000 Leuven, Belgium; ORCID: 0000-0002-4057-2236.

15

16 Key words: Wastewater based epidemiology (WBE), acute respiratory tract infection (ARI),  
17 respiratory panel, influenzavirus, adenovirus, RSV, entero/rhinovirus, EV-D68, coronavirus

18 Word count: 2768

19

## 20 **ABSTRACT**

### 21 ***Background***

22 Detailed information on the circulation of respiratory viruses in the community is crucial to gain  
23 better understanding of the burden of respiratory infections on society.

24 **Methods**

25 By using an in-house respiratory panel for simultaneous detection of 29 respiratory pathogens (22  
26 viruses and 7 bacteria/fungi), we explored the possibility to use wastewater sampling to monitor the  
27 circulation of respiratory pathogens at population level.

28 **Results**

29 We were able to detect all respiratory viruses included in the panel (influenza A, respiratory syncytial  
30 virus (RSV), human metapneumovirus (HMPV), parainfluenza viruses (PIV) 1-4, adenovirus (Adv),  
31 human bocavirus (HBoV), enterovirus/rhinovirus (EV/RV), enterovirus D68 (EV-D68), parechovirus  
32 (HPeV), human coronaviruses (HCoV)-NL63, -229E, -OC43, -HKU-1 and -SARS, cytomegalovirus (CMV)  
33 and herpes simplex virus (HSV)-1 and -2), except for influenza B and HCoV MERS which were not  
34 circulating in Belgium during the two year study period. An upsurge of EV-D68 infections in Europe in  
35 September 2021 was clearly reflected in the wastewater samples. For the viruses where  
36 epidemiological data on virus circulation in Belgium were available, these matched the wastewater  
37 data. The wastewater pretreatment that was used, optimized for viral enrichment, was as such not  
38 suited for the surveillance of bacteria and fungi.

39 **Conclusions**

40 Community circulation levels of respiratory viruses were well reflected in wastewater samples,  
41 indicating that wastewater-based epidemiology can be a valuable tool in the epidemiology and  
42 management of respiratory infections.

43

## 44 INTRODUCTION

45 Wastewater-based epidemiology (WBE) can be used as a non-invasive tool to monitor the circulation  
46 of pathogens within a population. Since various body fluids are discharged into wastewater systems,  
47 the method includes but is not limited to detection of fecally excreted viruses and bacteria. Several  
48 countries use regular testing of wastewater in the surveillance of poliovirus [1]. Investigation of  
49 sewage water can also be applied to monitor the circulation of other enteric viruses such as  
50 norovirus, hepatitis A virus and hepatitis E virus [2], [3]. Since the start of the COVID-19 pandemic,  
51 wastewater has also been used to follow circulation levels of SARS-CoV-2 and its different variants of  
52 concern (VOC) [4], [5]. For this purpose, we have collected samples from a regional sewage  
53 treatment plant in the region of Leuven (Belgium) since December 2020. We found wastewater  
54 based surveillance to be an important objective indicator of SARS-CoV-2 circulation in the  
55 community, which can prove to be highly valuable in times of reducing testing capacity or lower  
56 willingness to test [6].

57 Acute respiratory tract infections (ARIs), including pneumonia, constitute a major disease burden  
58 worldwide, especially in young children and the elderly. According to the WHO, lower respiratory  
59 infections were the world's most deadly communicable disease, ranked as the 4th leading cause of  
60 death globally in 2019 (so irrespective of the effect of the COVID-19 pandemic). Respiratory viruses,  
61 including influenza virus, EV/RV, RSV, HMPV, PIV, HBoV, Adv and HCoVs, are the leading cause of  
62 ARI's in children as well as in older adults [7]–[10]. A large proportion of respiratory infections do not  
63 lead to hospitalization or medical care seeking, and therefore go undetected. To gain a better  
64 understanding of the burden of respiratory viruses on society, it is important to obtain detailed  
65 information on their circulation in the community. This knowledge could allow a better prediction  
66 and management of major outbreaks, and could guide physicians in their diagnosis. The current  
67 approach is usually based on reporting by a limited number of sentinel physicians and labs, which can  
68 lead to bias in the available data.

69 To allow quick diagnosis of respiratory pathogens in immunocompromised and/or critically ill  
70 patients with serious lower respiratory infection, a respiratory panel (RP) for simultaneous detection  
71 of 22 respiratory viruses (influenza A, influenza B, RSV, HMPV, PIV-1 to -4, Adv, HBoV, RV/EV, EV-D68,  
72 HPeV, HCoV-NL63, -229E, -OC43, -HKU-1, -SARS and – MERS, CMV, HSV-1 and -2) and 7  
73 bacteria/fungi (*Mycoplasma pneumoniae*, *Coxiella burnetii*, *Chlamydia pneumoniae*, *Chlamydia*  
74 *psittaci*, *Streptococcus pneumoniae*, *Legionella pneumophila* and *Pneumocystis jiroveci*) was  
75 developed by the Department of Laboratory Medicine of the University Hospitals Leuven. Using this  
76 RP, we explored whether wastewater sampling can be used to monitor the circulation of respiratory  
77 pathogens at population level.

78

## 79 **METHODS**

### 80 ***Sampling***

81 Wastewater samples were collected on average weekly, starting December 6<sup>th</sup> 2020, from a  
82 large regional wastewater treatment plant (WWTP) in Leuven that treats municipal  
83 wastewater of approximately 115000 inhabitants. Samples (500 mL) of 24-hour composite  
84 influent wastewater were collected through a time-proportional automated sampler, which  
85 collects 50 mL of wastewater every 10 minutes in a large container. The samples were stored  
86 in a refrigerator at 4°C before transport to the laboratory.

### 87 ***Viral TNA extraction***

88 Virus concentration and filtration from the wastewater samples was performed as described  
89 previously [6]. Total nucleic acids (TNA) were extracted from 500 µL concentrated and  
90 filtered sewage samples or DNA/RNA free water (negative controls) using the MagMAX™  
91 Viral/Pathogen Nucleic Acid Isolation Kit on Kingfisher Flex-96 (ThermoFisher Scientific,  
92 Europe). TNA were eluted in 50 µL elution buffer. Extractions were done in duplicate to  
93 obtain sufficient volume of elute for all the tests performed.

### 94 ***Respiratory panel (RP)***

95 An in-house developed RP consisting of 12 real-time multiplex PCRs was performed on a  
96 QuantStudio 7 (Thermo Fisher Scientific, Waltham, MA, USA) in 96 well plates. The end  
97 volume of each PCR reaction mix was 20 µL consisting of 5 µL of TNA, 5 µL of master mix  
98 (TaqMan Fast Virus Mix) and 10 µL of primer/probe mix. Primer and probe sequences and  
99 final concentrations are provided in Supplementary table 1. The temperature profile used  
100 was 50°C for 10 minutes; 95°C for 20 seconds; 45 cycles composed of 95°C for 3 seconds and  
101 60°C for 30 seconds.

102 Specificity of this lab-developed RP was validated in a clinical context using External Quality

103 Control (EQC) samples, virus cultures and clinical respiratory samples.

104 ***Detection of PMMoV***

105 Human fecal indicator pepper mild mottle virus (PMMoV) was analyzed as an internal

106 extraction control, and to check for extensive differences in human waste input and/or

107 rainwater infiltration, as described previously [6], [11].

108

## 109 **RESULTS AND DISCUSSION**

110 Full RP results are listed in Supplementary table 2. The human fecal indicator PMMoV was detected  
111 in all wastewater samples with only limited variation in Ct values (Ct 22 to 26) (Fig. 1i), indicating  
112 there were no extensive differences in fecal input or wastewater dilution throughout the study.  
113 Although we did not determine the normalized pathogen concentrations using standard curves, the  
114 stable detection of PMMoV indicates that Ct values can be used as a proxy for semi-quantitative  
115 assessment of the pathogen load in our wastewater samples.

### 116 ***Influenzavirus (Fig. 1a)***

117 Whereas influenza B was not detected in any of the collected samples, influenza A was detected in  
118 only 1 sample in 2021 (dating from October 4<sup>th</sup> 2021), and was repeatedly detected between mid  
119 Februari and mid May 2022. This is in line with the influenza data collected by the network of  
120 sentinel physicians and laboratories, coordinated by the national public health institute of Belgium  
121 Sciensano, who reported a very mild influenza season 2020-2021, and a late influenza season 2021-  
122 2022 between end of Februari 2022 and end of April 2022. Only influenza A was detected by the  
123 sentinel labs during the 2021-2022 season [12].

### 124 ***RSV and HMPV (Fig. 1b)***

125 RSV was detected in all but one wastewater sample collected between March 8<sup>th</sup> and June 7<sup>th</sup> 2021.  
126 Sporadic detection occurred during the summer of 2021. As of mid October 2021, RSV was  
127 continuously detected until end of December 2021, and discontinuously in January 2022. From the  
128 end of February 2022 until the end of July 2022, RSV was present in almost all wastewater samples.  
129 This is in accordance with the data from the sentinel labs reported by Sciensano, which indicated a  
130 late RSV season in 2019-2020 and a low, almost continuous RSV presence up to week 31 (beginning  
131 of August) during 2021-2022 [12]. Since the end of August 2022, RSV was again detectable in  
132 wastewater, but no infections have been reported by Sciensano yet in the weekly bulletin of week  
133 40, which might be attributable to a delay in data reporting by the sentinel labs. HMPV was not

134 detected in the wastewater samples during the winter season 2020-2021, and was found in one  
135 sample during the summer of 2021. From the end of September until the end of December 2021,  
136 HMPV was nearly continuously present in the wastewater samples. HMPV is not included in the  
137 respiratory virus report of Sciensano, so no data on the circulation of HMPV from sentinel labs in  
138 Belgium are available.

139 In the past, we have studied the prevalence and seasonality of respiratory viruses in respiratory  
140 samples of ARI patients in the University Hospitals of Leuven, from 2011-2016 [13]. These data  
141 showed that the HMPV season had a median onset around mid-December (week 50), peaked in the  
142 beginning of April (week 14.5) and lasted until May (week 21). For RSV, the median start of the  
143 epidemic season was in the late fall (week 44), with a peak on average at the beginning of December  
144 (week 48), and ending at the beginning of Februari (week 5). This does not match the circulation  
145 patterns we now see in the wastewater samples. As for other respiratory viruses, the circulation of  
146 RSV and HMPV was impacted by the nonpharmacological interventions such as extensive hand  
147 hygiene, mask-wearing, and social distancing that were implemented globally in response to the  
148 COVID-19 pandemic [14]–[16]. This can account for alterations in levels as well as timing of virus  
149 circulation.

#### 150 ***Parainfluenzaviruses (Fig. 1c)***

151 Of the parainfluenzaviruses, PIV-1 was not detected in 2021 and only sporadically in 2022. PIV-2 was  
152 detected almost continuously during the fall of 2021, then more sporadically during the winter 2021-  
153 2022, and again almost continuously as off mid March 2022 until the end of August. PIV-3 was  
154 detected in all wastewater samples from the beginning of Februari 2021 until the beginning of May  
155 2021. As of the beginning of August 2021, PIV-3 was again detectable in almost all wastewater  
156 samples up to the beginning of September 2022. PIV-4 was detectable in almost all samples between  
157 the August 2021 and December 2021, and again as of September 2022, and only sporadically in  
158 samples in between. In the data on respiratory pathogens detected by sentinel labs, shared by  
159 Sciensano, a peak in PIV circulation is visible between mid Februari 2021 and the beginning of April



160 2021. During the season 2021-2022, the PIV circulation was more spread out, with no clear peak  
161 being present [12]. Data on circulation of different PIV subtypes is not available from Sciensano. In  
162 our study on seasonality of respiratory viruses in ARI samples, we found that the 4 subtypes of PIV  
163 had their seasonal peaks at different moments during the year. Subtype 3 had the tendency to have  
164 its seasonal peaks around April/May, subtype 4 around December, while subtypes 1 and 2 did not  
165 present with a clear seasonal pattern [13]. According to our wastewater data, this seasonality was  
166 more or less maintained in 2021 (with a spring peak of PIV-3 and an (earlier) winter peak of PIV-4),  
167 but in 2022 PIV-3 was more continuously present.

#### 168 **Adenovirus and bocavirus (Fig. 1d)**

169 Both Adv and HBoV were detected consistently and in similar concentrations in all wastewater  
170 samples during the entire study. This is in accordance with the continuous Adv circulation in 2020-  
171 2021 and 2021-2022 reported by Sciensano, and with our previous study on ARI samples, where we  
172 found Adv infections to be present throughout the year, with a slight downfall during the Belgian  
173 summer season (week 25-38) [12], [13]. The circulation of HBoV is not reported by Sciensano, but its  
174 global prevalence has been reported from many countries, including Belgium [17]. To date, 4  
175 genotypes of HBoV have been identified, all of which can be detected by the primers and probe  
176 located in the highly conserved NP-1 gene, used in our respiratory panel [18]. HBoV1 was mainly  
177 identified in respiratory samples from children with ARI [19], whereas HBoV2 is associated with  
178 clinical symptoms of patients with gastroenteritis [20]. All HBoV genotypes are known to be present  
179 in stool, and HBoV can frequently be detected in sewage samples [21]. Adv infections can also cause  
180 gastrointestinal symptoms, even when the primary site of involvement is the respiratory tract, and  
181 some serotypes (notably Adv-40 and -41) have an affinity for the gastrointestinal tract, with  
182 predominant symptoms of gastroenteritis or diarrhea [22]. The presence of HBoV and Adv in our  
183 wastewater samples is therefore likely linked to enteric infections rather than respiratory infections.

#### 184 **Enterovirus/rhinovirus, EV-D68 and parechovirus (Fig. 1e)**

185 Of the 15 classified species of enterovirus, EV A–D and RV A–C infect humans and are a frequent  
186 cause of respiratory infections. The fecal-oral route is the most common mode of EV transmission  
187 and the primary sites of replication are the gastrointestinal and respiratory tract [23]. Most infections  
188 are mild with fever and/or common cold symptoms, but some types, especially those belonging to EV  
189 A–D, may cause meningitis, encephalitis, paralysis, neonatal sepsis, myalgia, myocarditis, or  
190 exanthema. Of note, EV-D68 has recently been shown to cause large outbreaks of more severe  
191 disease with complications such as acute flaccid myelitis [24], [25]. Although EV/RV in general were  
192 detected continuously in the wastewater, EV-D68 detection was limited to early September 2021  
193 until early December 2021, with the highest concentrations in October 2021. These data provide  
194 indications for an outbreak of EV-D68 in the region of Leuven during the fall of 2021, which is in line  
195 with the upsurge of EV-D68 infections in Europe as of September 2021, reported by the ECDC [26]. A  
196 comparison with the numbers of EV-D68 positive samples tested in the University Hospitals Leuven  
197 showed that a total of 20 patients were diagnosed with EV-D68 in 2021, all of which between  
198 October and December 2021 (unpublished data). There was a sporadic EV-D68 detection in January  
199 2022, and a brief resurgence in April 2022. As of mid September 2022, EV-D68 was again detected in  
200 the wastewater samples, which could indicate the start of a new EV-D68 upsurge in the autumn of  
201 2022.

202 Like EV/RV, HPeV was present in all samples during the entire study period. HPeV infections without  
203 specific symptoms are very common in children, but disease manifestations ranging from  
204 gastroenteritis and respiratory infections to neurological disease, particularly in neonates, have been  
205 described in association with HPeV [27]. Given their involvement in gastrointestinal infections, HPeVs  
206 are frequently detected in sewage samples, where their presence can be an early indicator of clinical  
207 cases, including CNS-infections [3], [28]. However, since HPeV were continuously detected in our  
208 wastewater samples, indicating a year-round circulation of HPeV in the community, this  
209 measurement does not seem useful as an early warning in our setting.

210 **Coronaviruses (Fig. 1f and 1g)**

211 With the SARS-CoV assay in the respiratory panel, targeting a conserved region in the ORF1ab  
212 polyprotein gene to allow detection of both SARS-CoV-1 and -2, we did not detect SARS-CoV-2 until  
213 the end of September 2021 and only discontinuously thereafter. We also used the 2019-nCoV CDC  
214 EUA kit, targeting two regions of the N-gene, for detection of SARS-CoV-2 in all wastewater samples  
215 and were able to detect SARS-CoV-2 viral RNA at all measured timepoints, with viral RNA levels  
216 largely corresponding to the number of positive cases in Leuven [6]. This indicates that, although  
217 suitable in a clinical context, the universal RP SARS-CoV assay is not sensitive enough for  
218 environmental surveillance.

219 As expected, the highly pathogenic MERS-CoV was not detected at any timepoint, since MERS-CoV  
220 infections have not been reported in Europe for over 4 years now [29], [30].

221 Of the 4 endemic seasonal coronaviruses infecting humans, HCoV-NL-63 was only detected in one  
222 sample whereas HCoV-229E and HCoV-OC43 were present in 72% and 84% of all samples  
223 respectively. HCoV-HKU-1 was only detected as off the end of November 2021. These endemic  
224 coronaviruses are mainly associated with mild and self-limiting upper respiratory tract infections,  
225 accounting for about 15–30% of common cold cases, and normally circulate with annual peaks of  
226 infections in the winter months [31], [32]. Besides the occurrence in the respiratory tract, all endemic  
227 HCoVs can also be detected in stool samples but they do not seem to be a major cause of  
228 gastroenteritis, and this detection is most likely explained by the presence of ingested virus particles  
229 from the respiratory tract rather than resulting from productive replication in intestinal tissue [31]. In  
230 regions with a temperate climate, such as Belgium, the highest activity of endemic HCoVs is observed  
231 during the winter months [32]. As is the case for other respiratory viruses, their circulation pattern  
232 has been affected by contact restrictions and hygienic measures that were implemented in reaction  
233 to the COVID-19 outbreak, especially during the 1<sup>st</sup> year after the emergence of SARS-CoV-2. This  
234 could account for the lower levels of endemic HCoV's detected in the wastewater samples up to the  
235 spring of 2021.

236 **Herpesviruses (Fig. 1h)**

237 HSV can cause influenza like illness, but also meningitis and encephalitis. CMV is a ubiquitous  
238 pathogen mainly infecting children, with childhood infections usually going unnoticed whereas  
239 infections in adults can be more severe, especially in the immunocompromised. There are only  
240 limited data available on the presence of human herpesviruses in wastewater, especially for HSV  
241 [33]. In our study, HSV-1 and CMV were only sporadically detected, each at 4 scattered timepoints,  
242 and HSV-2 was only detected in a single wastewater sample.

### 243 **Bacteria and fungi**

244 In view of SARS-CoV-2 and polio surveillance, the current method was developed for optimal  
245 retrieval of viral material, by including filtration using a 1 µm syringe filter. The drawback of this viral  
246 enrichment is that the majority of bacterial and fungal material is lost prior to extraction. Although  
247 we were able to detect bacteria/fungi in some of the samples, we consider this method unsuited to  
248 confidently detect their presence in wastewater.

249

## 250 **CONCLUSION**

251 By using the RP on our sample collection spanning almost 2 years, we were able to detect the  
252 presence and seasonal variation for most of the tested respiratory viruses. This indicates that  
253 wastewater sampling could provide a means to monitor the circulation of respiratory pathogens at  
254 population level, and provide an early warning signal in case of local upsurges. By using wastewater  
255 samples, the inherent bias posed by data reporting by limited numbers of sentinel labs can be  
256 circumvented.

257


## 258 **FIGURE LEGENDS**

259 **Figure 1. Respiratory viruses in wastewater (Aquafin, Leuven).**

260 Evolution of viruses detected by the respiratory panel from December 2020 to September 2022, as  
261 captured by the Ct value of targeted PCR assays performed on wastewater. Plots were generated  
262 using R and the ggplot2 package.



263



264

## 265 REFERENCES

- 266 [1] T. Hovi, L. M. Shulman, H. Van Der Avoort, J. Deshpande, M. Roivainen, and E. M. De  
 267 Gourville, "Role of environmental poliovirus surveillance in global polio eradication and  
 268 beyond," *Epidemiol. Infect.*, vol. 140, no. 1, pp. 1–13, 2012, doi:  
 269 10.1017/S095026881000316X.
- 270 [2] M. Hellmér *et al.*, "Detection of pathogenic viruses in sewage provided early warnings of  
 271 hepatitis A virus and norovirus outbreaks," *Appl. Environ. Microbiol.*, vol. 80, no. 21, pp. 6771–  
 272 6781, 2014, doi: 10.1128/AEM.01981-14.
- 273 [3] A. Thongprachum *et al.*, "Detection of nineteen enteric viruses in raw sewage in Japan,"  
 274 *Infect. Genet. Evol.*, vol. 63, no. May, pp. 17–23, 2018, doi: 10.1016/j.meegid.2018.05.006.
- 275 [4] S. Agrawal *et al.*, "Prevalence and circulation patterns of SARS-CoV-2 variants in European  
 276 sewage mirror clinical data of 54 European cities," *Water Res.*, vol. 214, no. February, p.  
 277 118162, 2022, doi: 10.1016/j.watres.2022.118162.

- 278 [5] G. Medema, L. Heijnen, G. Elsinga, R. Italiaander, and A. Brouwer, "Presence of SARS-  
279 Coronavirus-2 RNA in Sewage and Correlation with Reported COVID-19 Prevalence in the Early  
280 Stage of the Epidemic in the Netherlands," *Environ. Sci. Technol. Lett.*, vol. 7, no. 7, pp. 511–  
281 516, 2020, doi: 10.1021/acs.estlett.0c00357.
- 282 [6] M. Bloemen *et al.*, "Detection Of SARS-COV-2 Variants Of Concern In Wastewater Of Leuven,  
283 Belgium," *medRxiv*, p. 2022.05.12.22274823, May 2022, doi: 10.1101/2022.05.12.22274823.
- 284 [7] G. Comach *et al.*, "Sentinel Surveillance of Influenza-Like Illness in Two Hospitals in Maracay,  
285 Venezuela: 2006-2010," *PLoS One*, vol. 7, no. 9, pp. 2006–2010, 2012, doi:  
286 10.1371/journal.pone.0044511.
- 287 [8] D. Wang *et al.*, "Viral Etiology of Medically Attended Influenza-Like Illnesses in Children Less  
288 Than 5 Years Old in Suzhou, China," *J. Med. Virol.*, vol. 88, pp. 1334–1340, 2016, doi:  
289 10.1002/jmv.24480.
- 290 [9] T. Shi *et al.*, "The etiological role of common respiratory viruses in acute respiratory infections  
291 in older adults: A systematic review and meta-analysis," *J. Infect. Dis.*, vol. 222, no. Xx Xxxx,  
292 pp. S563–S569, 2020, doi: 10.1093/INFDIS/JIY662.
- 293 [10] K. Otani *et al.*, "Incidence of lower respiratory tract infection and associated viruses in a birth  
294 cohort in the Philippines," *BMC Infect. Dis.*, vol. 22, no. 1, pp. 1–11, 2022, doi:  
295 10.1186/s12879-022-07289-3.
- 296 [11] M. Kitajima, H. P. Sassi, and J. R. Torrey, "Pepper mild mottle virus as a water quality  
297 indicator," vol. 1, p. 19, 2018, doi: 10.1038/s41545-018-0019-5.
- 298 [12] Bossuyt Nathalie *et al.*, "Weekly bulletin respiratory infections." <https://epidemiologie.wiv-isp.be/ID/diseases/Pages/Influenza.aspx>  
299
- 300 [13] K. Ramaekers *et al.*, "Prevalence and seasonality of six respiratory viruses during five  
301 consecutive epidemic seasons in Belgium," *J. Clin. Virol.*, vol. 94, no. March, pp. 72–78, 2017,  
302 doi: 10.1016/j.jcv.2017.07.011.
- 303 [14] M. Stein *et al.*, "Human metapneumovirus prevalence during 2019-2021 in Israel is influenced  
304 by the COVID-19 pandemic," *Int. J. Infect. Dis.*, vol. 120, pp. 205–209, Jul. 2022, doi:  
305 10.1016/j.ijid.2022.04.037.
- 306 [15] H. J. Shi *et al.*, "Effects of Non-Pharmacological Interventions on Respiratory Viruses Other  
307 Than SARS-CoV-2: Analysis of Laboratory Surveillance and Literature Review From 2018 to  
308 2021," *J. Korean Med. Sci.*, vol. 37, no. 21, 2022, doi: 10.3346/jkms.2022.37.e172.
- 309 [16] Y. Li, X. Wang, B. Cong, S. Deng, D. R. Feikin, and H. Nair, "Understanding the Potential Drivers  
310 for Respiratory Syncytial Virus Rebound during the Coronavirus Disease 2019 Pandemic," *J.*  
311 *Infect. Dis.*, vol. 225, no. 6, pp. 957–964, Mar. 2022, doi: 10.1093/infdis/jiab606.
- 312 [17] D. Polo, A. Lema, E. Gándara, and J. L. Romalde, "Prevalence of human bocavirus infections in  
313 Europe. A systematic review and meta-analysis," *Transbound. Emerg. Dis.*, no. July, pp. 1–11,  
314 2021, doi: 10.1111/tbed.14233.
- 315 [18] F. Neske *et al.*, "Real-time PCR for diagnosis of human bocavirus infections and phylogenetic  
316 analysis," *J. Clin. Microbiol.*, vol. 45, no. 7, pp. 2116–2122, 2007, doi: 10.1128/JCM.00027-07.
- 317 [19] Q. B. Lu *et al.*, "Epidemic and molecular evolution of human bocavirus in hospitalized children  
318 with acute respiratory tract infection," *Eur. J. Clin. Microbiol. Infect. Dis.*, vol. 34, no. 1, pp. 75–  
319 81, 2015, doi: 10.1007/s10096-014-2215-7.
- 320 [20] R. De *et al.*, "Risk of acute gastroenteritis associated with human bocavirus infection in

- 321 children: A systematic review and meta-analysis,” *PLoS One*, vol. 12, no. 9, pp. 1–11, 2017,  
322 doi: 10.1371/journal.pone.0184833.
- 323 [21] T. Booranathawornsom, K. Pombubpa, M. Tipayamongkholgul, and L. Kittigul, “Molecular  
324 characterization of human bocavirus in recycled water and sewage sludge in Thailand,” *Infect.*  
325 *Genet. Evol.*, vol. 100, no. March, p. 105276, 2022, doi: 10.1016/j.meegid.2022.105276.
- 326 [22] J. P. Lynch Iii, A. E. Kajon, and S. K. Singh, “Adenovirus: Epidemiology, Global Spread of Novel  
327 Serotypes, and Advances in Treatment and Prevention,” *Semin. Respir. Crit. Care Med.*, vol.  
328 37, no. 4, pp. 586–602, 2016, doi: 10.1055/s-0036-1584923.
- 329 [23] S. Cordey *et al.*, “Comparative analysis of viral shedding in pediatric and adult subjects with  
330 central nervous system-associated enterovirus infections from 2013 to 2015 in Switzerland,”  
331 *J. Clin. Virol.*, vol. 89, pp. 22–29, 2017, doi: 10.1016/j.jcv.2017.01.008.
- 332 [24] K. Messacar, M. J. Abzug, and S. R. Dominguez, “2014 outbreak of enterovirus D68 in North  
333 America,” *J. Med. Virol.*, vol. 88, no. 5, pp. 739–745, May 2016, doi: 10.1002/jmv.24410.
- 334 [25] S. B. Larsson, D. Vracar, M. Karlsson, J. Ringlander, and H. Norder, “Epidemiology and clinical  
335 manifestations of different enterovirus and rhinovirus types show that EV-D68 may still have  
336 an impact on severity of respiratory infections,” *J. Med. Virol.*, vol. 94, no. 8, pp. 3829–3839,  
337 Aug. 2022, doi: 10.1002/jmv.27767.
- 338 [26] K. S. M. Benschop *et al.*, “Re-emergence of enterovirus d68 in europe after easing the covid-  
339 19 lockdown, september 2021,” *Eurosurveillance*, vol. 26, no. 45, 2021, doi: 10.2807/1560-  
340 7917.ES.2021.26.45.2100998.
- 341 [27] H. Harvala and P. Simmonds, “Human parechoviruses: Biology, epidemiology and clinical  
342 significance,” *Journal of Clinical Virology*, vol. 45, no. 1. pp. 1–9, May 2009. doi:  
343 10.1016/j.jcv.2009.03.009.
- 344 [28] H. Harvala *et al.*, “Comparison of diagnostic clinical samples and environmental sampling for  
345 enterovirus and parechovirus surveillance in Scotland, 2010 to 2012,” *Eurosurveillance*, vol.  
346 19, no. 15, pp. 1–9, 2014, doi: 10.2807/1560-7917.ES2014.19.15.20772.
- 347 [29] ECDC, “Communicable disease threats report, Week 27, 3-9 July 2022”.
- 348 [30] ECDC, “Rapid risk assessment: Severe respiratory disease associated with Middle East  
349 respiratory syndrome coronavirus (MERS-CoV), 22nd update,” 2018.  
350 [https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-severe-respiratory-](https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-severe-respiratory-disease-associated-middle-east-11)  
351 [disease-associated-middle-east-11](https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-severe-respiratory-disease-associated-middle-east-11)
- 352 [31] V. M. Corman, D. Muth, D. Niemeyer, and C. Drosten, “Hosts and Sources of Endemic Human  
353 Coronaviruses,” *Adv. Virus Res.*, vol. 100, pp. 163–188, Jan. 2018, doi:  
354 10.1016/BS.AIVIR.2018.01.001.
- 355 [32] Y. Li, X. Wang, and H. Nair, “Global seasonality of human seasonal coronaviruses: A clue for  
356 postpandemic circulating season of severe acute respiratory syndrome coronavirus 2?,” *J.*  
357 *Infect. Dis.*, vol. 222, no. 7, pp. 1090–1097, 2020, doi: 10.1093/infdis/jjaa436.
- 358 [33] C. McCall, H. Wu, B. Miyani, and I. Xagorarakis, “Identification of multiple potential viral  
359 diseases in a large urban center using wastewater surveillance,” *Water Res.*, vol. 184, p.  
360 116160, 2020, doi: 10.1016/j.watres.2020.116160.
- 361 [34] A. Clancy, B. Crowley, H. Niesters, and C. Herra, “The development of a qualitative real-time  
362 RT-PCR assay for the detection of hepatitis C virus,” *Eur. J. Clin. Microbiol. Infect. Dis.*, vol. 27,  
363 no. 12, pp. 1177–1182, Dec. 2008, doi: 10.1007/s10096-008-0556-9.



- 364 [35] J. Kuypers, N. Wright, and R. Morrow, "Evaluation of quantitative and type-specific real-time  
365 RT-PCR assays for detection of respiratory syncytial virus in respiratory specimens from  
366 children," *J. Clin. Virol.*, vol. 31, pp. 123–129, 2004, doi: 10.1016/j.jcv.2004.03.018.
- 367 [36] W. A. Nix *et al.*, "Detection of all known parechoviruses by real-time PCR," *J. Clin. Microbiol.*,  
368 vol. 46, no. 8, pp. 2519–2524, Aug. 2008, doi: 10.1128/JCM.00277-08.
- 369 [37] H. G. M. Niesters, "Molecular and diagnostic clinical virology in real time," *Clin. Microbiol.*  
370 *Infect.*, vol. 10, no. 1, pp. 5–11, 2004, doi: 10.1111/j.1469-0691.2004.00699.x.
- 371 [38] A. Tiveljung-Lindell *et al.*, "Development and implementation of a molecular diagnostic  
372 platform for daily rapid detection of 15 respiratory viruses," *J. Med. Virol.*, vol. 81, no. 1, pp.  
373 167–175, Jan. 2009, doi: 10.1002/JMV.21368.
- 374 [39] L. J. R. Van Elden *et al.*, "Frequent Detection of Human Coronaviruses in Clinical Specimens  
375 from Patients with Respiratory Tract Infection by Use of a Novel Real-Time Reverse-  
376 Transcriptase Polymerase Chain Reaction," *J. Infect. Dis.*, vol. 189, pp. 652–659, 2004.
- 377 [40] A. Piralla, A. Girello, M. Premoli, and F. Baldanti, "A new real-time reverse transcription-PCR  
378 assay for detection of human enterovirus 68 in respiratory samples," *J. Clin. Microbiol.*, vol.  
379 53, no. 5, pp. 1725–1726, May 2015, doi: 10.1128/JCM.03691-14/FORMAT/EPUB.
- 380 [41] M. Panning *et al.*, "High throughput detection of *Coxiella burnetii* by real-time PCR with  
381 internal control system and automated DNA preparation," *BMC Microbiol.*, vol. 19, no. 8,  
382 2008, doi: 10.1186/1471-2180-8-77.
- 383 [42] V. M. Corman *et al.*, "Detection of a novel human coronavirus by real-time reverse-  
384 transcription polymerase chain reaction," *Eurosurveillance*, vol. 17, no. 39, Sep. 2012, doi:  
385 10.2807/ese.17.39.20285-en.
- 386 [43] J. Hardick *et al.*, "Real-Time PCR for *Chlamydia pneumoniae* Utilizing the Roche Lightcycler  
387 and a 16S rRNA Gene Target," *J. Mol. Diagnostics*, vol. 6, no. 2, 2004.
- 388 [44] A. Ménard, M. Clerc, A. Subtil, F. Mégraud, C. Bébéar, and B. De Barbeyrac, "Development of a  
389 real-time PCR for the detection of *Chlamydia psittaci*," *J. Med. Microbiol.*, vol. 55, no. Pt 4, pp.  
390 471–473, 2006, doi: 10.1099/JMM.0.46335-0.
- 391 [45] M. Da *et al.*, "Evaluation and Improvement of Real-Time PCR Assays Targeting *lytA*, *ply*, and  
392 *psaA* Genes for Detection of Pneumococcal DNA," *J. Clin. Microbiol.*, vol. 45, no. 8, pp. 2460–  
393 2466, 2007, doi: 10.1128/JCM.02498-06.
- 394

395 **Supplementary table 1:** Primers and probes used in the 12 multiplex PCR reactions of the respiratory panel.

| Multiplex PCR | Pathogen      | Primer/probe   | Primer/probe sequence (5' → 3')     | Concentration (nM) | Target gene                      | Amplicon size (bp) |
|---------------|---------------|----------------|-------------------------------------|--------------------|----------------------------------|--------------------|
| RP1           | Influenza A   | Forward primer | TTCATGGAATGGCTAAAGACAAG             | 300                | Matrix protein gene              | 116                |
|               |               | Reverse primer | CAAAGCGTCTACGCTGCAGT                | 300                |                                  |                    |
|               |               | Probe          | FAM-TTCACGCTCACCGTGC-MGB            | 200                |                                  |                    |
|               | Influenza B   | Forward primer | AATACGGTGGATTAACAAAAGCA             | 300                | Hemagglutinin gene               | 170                |
|               |               | Reverse primer | ACCAGCAATAGCTCCGAAGAA               | 300                |                                  |                    |
|               |               | Probe          | NED-TATATTTGGTTCCATTGGC-MGB         | 200                |                                  |                    |
|               | PDV (RNA IC)  | Forward primer | GGTGGTGCCTTTTACAAGAAC [34]          | 250                | Hemagglutinin gene               | 83                 |
|               |               | Reverse primer | ATCTTCTTCTCAACCTCGTCC [34]          | 250                |                                  |                    |
|               |               | Probe          | VIC-ATGCAAGGGCCAATT-MGB [34]        | 100                |                                  |                    |
| RP2           | RSV A + RSV B | Forward primer | AATACGCCAAATCTAACCACTTACA [35]      | 300                | RNA polymerase gene              | 94                 |
|               |               | Reverse primer | GCCAAGGAAGCATGCAATAAA [35]          | 300                |                                  |                    |
|               |               | Probe A        | FAM-TGATGTGCTATTGTGCACTA-MGB [35]   | 100                |                                  |                    |
|               |               | Probe B        | FAM-CACTATTCCTACTAAAGATGTC-MGB [35] | 100                |                                  |                    |
|               | HMPV          | Forward primer | GCGTYAGCTTCAGTCAATTCAA              | 500                | Fusion protein gene              | 75                 |
|               |               | Reverse primer | TGTTATYCCWGCATTGTCTGA               | 500                |                                  |                    |
|               |               | Probe          | NED-CTAAATGTTGTGCGGCAAT-MGB         | 200                |                                  |                    |
| RP3           | PIV-1         | Forward primer | CCTTCATTATCAATTGGTGATGCA            | 500                | Hemagglutinin-neuraminidase gene | 180                |
|               |               | Reverse primer | CCTGTTGTCGTTGATGTCATAGGT            | 500                |                                  |                    |
|               |               | Probe          | FAM-TCAAACCTAATCACTCAAGGAT-MGB      | 100                |                                  |                    |
|               | PIV-2         | Forward primer | CATTTACCTAAGTGATGGAATCAATCG         | 500                | Hemagglutinin-neuraminidase gene | 141                |
|               |               | Reverse primer | GCAAGTCTCAGTTCAGCTAGATCAGT          | 500                |                                  |                    |
|               |               | Probe          | NED-AAAGCTGTTCACTACTG-MGB           | 150                |                                  |                    |
| RP4           | PIV-3         | Forward primer | CAAAGTTGATGAAAGATCAGATTATGC         | 500                | Hemagglutinin-neuraminidase gene | 169                |
|               |               | Reverse primer | GTAGTATATCCCTGGTCCAACAGATG          | 500                |                                  |                    |
|               |               | Probe          | FAM-CAATCTCRACAACAAGATT-MGB         | 100                |                                  |                    |
|               | PIV-4         | Forward primer | GGAGCAAAAGAYTCATACACAATAACTACT      | 500                | Hemagglutinin-neuraminidase gene | 116                |
|               |               | Reverse primer | CTAGGAA TTAARATTCACAATCTTCAGAA      | 500                |                                  |                    |
|               |               | Probe          | NED-AAATGCACTCTGTATAAGTC-MGB        | 150                |                                  |                    |
| RP5           | Adenovirus    | Forward primer | TYGARGTGGAYCCATGGAYGAG              | 800                | Hexon gene                       | 112                |
|               |               | Reverse primer | CGCAGGTAGACBGCYTCRATGA              | 800                |                                  |                    |

|     |                       |                  |   |     |  |         |
|-----|-----------------------|------------------|---|-----|--|---------|
|     |                       | Probe 1          | FAM-ACGTCGAAGACTTC-MGB                      | 100 | Polyprotein gene                           | 150-154 |
|     |                       | Probe 2          | FAM-ACGTCGAAAACCTTC-MGB                     | 100 |  |         |
|     |                       | Probe 3          | FAM-CACGTCAAAGACTTC-MGB                     | 100 |  |         |
|     | Rhino-<br>enterovirus | Forward primer 1 | CAWGGTGYGAAGAGYCTATTGAGCT                   | 500 |  |         |
|     |                       | Forward primer 2 | GTGTGAAGASCCSMGTGYGCT                       | 500 |  |         |
|     |                       | Reverse primer   | GAAACACGGACACCCAAAGTAGT                     | 500 |  |         |
|     |                       | Probe            | VIC-TCCGGCCCTGAATGYGGCTAA-TAMRA             | 200 |  |         |
| RP6 | CMV                   | Forward primer   | CGTAACGTGGACCTGACGTTT                       | 250 | Major capsid protein gene                  | 148     |
|     |                       | Reverse primer   | CACGGTCCCGTTTAGCA                           | 250 |  |         |
|     |                       | Probe            | FAM-TATCTGCCCGAGATCGCGTTACA-TAMRA           | 200 |  |         |
|     | Parechovirus          | Forward primer   | CASWWGCCTCTGGGCCAAAAAG [36]                 | 500 | Polyprotein gene                           | 189     |
|     |                       | Reverse primer   | GGCCCCWGRTCAGATCCAYAGT [36]                 | 500 |  |         |
|     |                       | Probe            | Cy5-CCTRYGGGTA CCTYCWGGGCATCCTTC-BHQ3 [36]  | 200 |  |         |
|     | PhHV-1<br>(DNA IC)    | Forward primer   | GGGCGAATCACAGATTGAATC [37]                  | 100 | Glycoprotein B gene                        | 89      |
|     |                       | Reverse primer   | GCGTTCCAAACGTACCAA [37]                     | 100 |  |         |
|     |                       | Probe            | VIC-TCCGCCACCATCTG-MGB                      | 100 |  |         |
| RP7 | HCoV NL63             | Forward primer   | CAGGGCTGACAAGCCTTCTCA [38]                  | 500 | Nucleocapsid protein gene                  | 144     |
|     |                       | Reverse primer   | GCATCAACACCAATTCTGAACAAGA [38]              | 500 |  |         |
|     |                       | Probe            | FAM-CGTTGGAAGCGTGTTCCTACCAGAGAGG-BHQ-1 [38] | 200 |  |         |
|     | HCoV 229E             | Forward primer   | TGGAAGTGCAAGGTGTTGTGGC [38]                 | 500 | Nucleocapsid protein gene                  | 99      |
|     |                       | Reverse primer   | TGACTATCAAACAGCATA GCAGCTG [38]             | 500 |  |         |
|     |                       | Probe            | Cy5-CCACAATTTGCTGAGCTTGTCGGCTC-BHQ-3 [38]   | 200 |  |         |
|     | HCoV OC43             | Forward primer   | CGATGAGGCTATTCGACTAGGT [39]                 | 500 | Nucleocapsid protein gene                  | 75      |
|     |                       | Reverse primer   | CCTTCCTGAGCCTTCAATATAGTAACC [39]            | 500 |  |         |
|     |                       | Probe            | VIC-TCCGCCTGGCACGGTACTCCCT-TAMRA [39]       | 200 |  |         |
| RP8 | HSV-1 + HSV-2         | Forward primer   | AACCTGGGRTTCTGATGCA                         | 250 | Nonfunctional glycoprotein D<br>gene (US6) | 84      |
|     |                       | Reverse primer   | CTCCGTCCAGTCGTTTATCTTAC                     | 250 |  |         |
|     |                       | Probe HSV-1      | FAM-TTTGAGACCGCCGGCACGTAC-BHQ-1             | 100 |  |         |
|     |                       | Probe HSV-2      | Cy5-CCTTCGAGACCGGGTACGTA-BHQ-3              | 100 |  |         |
|     | Enterovirus<br>D68    | Forward primer   | TGGCGGCTACTCATGG [40]                       | 500 | Polyprotein gene                           | 64      |
|     |                       | Reverse primer   | AATAGACTCTTACACCTTGTTCATGT [40]             | 500 |  |         |
|     |                       | Probe            | NED-AAAA CCATGAGACGCT-MGB [40]              | 200 |  |         |
|     | HCoV SARS             | Forward primer   | CWGGCATAACWAAGGACATGACCTA                   | 500 | ORF1ab polyprotein gene                    | 147     |
|     |                       | Reverse primer   | CKACATCRAAGCCAATCCA                         | 500 |  |         |
|     |                       | Probe            | VIC-TTTATCACCCGCGAAGAA-MGB                  | 200 |  |         |

|      |                                 |                |  |     |   |     |
|------|---------------------------------|----------------|--|-----|---|-----|
| RP9  | <i>Mycoplasma pneumoniae</i>    | Forward primer | AGGCTTCAAGTGACAAAAGTGAC                        | 250 | Adhesin P1 gene                         | 76  |
|      |                                 | Reverse primer | GATTGTYCCTGCTGGYCCAT                           | 250 |   |     |
|      |                                 | Probe          | FAM-ACCACACCAAGTTCA-MGB                        | 200 |   |     |
|      | HCoV HKU1                       | Forward primer | CACTTCTATTCCTCCGATGTTTC [38]                   | 500 | Nucleocapsid protein gene               | 129 |
|      |                                 | Reverse primer | TTAGAAGCAGACCTTCTGAGCC [38]                    | 500 |   |     |
|      |                                 | Probe          | Cy5-CGCCTGGTACGATTTTGCCTCAAGGCT-BHQ-3 [38]     | 200 |   |     |
| RP10 | <i>Pneumocystis jirovecii</i>   | Forward primer | GCACTGAATACTCGAGGGAGTATG                       | 250 | Large subunit ribosomal RNA gene        | 145 |
|      |                                 | Reverse primer | TTGGGAGCTTTAATTACTGTTCTGG                      | 250 |   |     |
|      |                                 | Probe          | FAM-TGTTTCCCTTTCGACTATC-MGB                    | 200 |   |     |
|      | <i>Coxiella burnetii</i>        | Forward primer | CGATAGCCCGATAAGCATCAAC [41]                    | 250 | IS1111 transposase gene                 | 88  |
|      |                                 | Reverse primer | TGCATTGATATCCGGCATC [41]                       | 250 |   |     |
|      |                                 | Probe          | NED-TCATCAAGGCACCAATG-MGB [41]                 | 200 |   |     |
|      | HCoV MERS                       | Forward primer | GCAACGCGCGATTGATT [42]                         | 500 | Envelope gene (upE)                     | 92  |
|      |                                 | Reverse primer | GCCTCTACACGGACCCATA [42]                       | 500 |   |     |
|      |                                 | Probe          | Cy5-CTCTTACATAATCGCCCCGAGCTCG-BHQ-3 [42]       | 200 |   |     |
| RP11 | <i>Chlamydia pneumoniae</i>     | Forward primer | CATCCGTGTCGGAGCTAACGT [43]                     | 250 | 16S rRNA gene                           | 184 |
|      |                                 | Reverse primer | TGCGGAAAGCTGTATTCTACAGTT [43]                  | 250 |   |     |
|      |                                 | Probe          | FAM-ATGCCCGCTGAGGAGTACACTCGC-BHQ1 [43]         | 200 |   |     |
|      | <i>Chlamydia psittaci</i>       | Forward primer | GCCATCATGCTTGTTCGTTT [44]                      | 250 | Inclusion membrane protein A gene       | 74  |
|      |                                 | Reverse primer | CGGCGTGCCACTTGAGA [44]                         | 250 |   |     |
|      |                                 | Probe          | VIC-TTGTATTATGGTGATTCAGGA-MGB [44]             | 200 |   |     |
|      | <i>Streptococcus pneumoniae</i> | Forward primer | ACGCAATCTAGCAGATGAAGCA [45]                    | 250 | Autolysin gene (lytA)                   | 75  |
|      |                                 | Reverse primer | TCGTGCGTTTTAATCCAGCT [45]                      | 250 |   |     |
|      |                                 | Probe          | Cy5-TGCCGAAAACGCTTGATACAGGGAG-BHQ3 [45]        | 200 |   |     |
| RP12 | <i>Legionella pneumophila</i>   | Forward primer | TCCGGAAGCAATGGCTAAAG                           | 250 | Macrophage infectivity potentiator gene | 69  |
|      |                                 | Reverse primer | TGCTGTTCGGTTAAAGCCAAT                          | 250 |   |     |
|      |                                 | Probe          | FAM-CATGCAAGACGCTATGAGTGCGCT-TAMRA             | 200 |   |     |
|      | Bocavirus                       | Forward primer | GCACAGCCACGTGACGAA [18]                        | 250 | Nonstructural protein 1 gene            | 76  |
|      |                                 | Reverse primer | TGGACTCCCTTTCTTTGTAGGA [18]                    | 250 |   |     |
|      |                                 | Probe          | Cy5-TGAGCTCAGGGAATATGAAAGACAAGCATCG-BHQ-3 [18] | 200 |   |     |

396 Base ambiguity codes: R: A or G; Y: C or T; W: A or T; S: C or G; K: G or T

397 PDV: phocine distemper virus; RSV: respiratory syncytial virus; IC: internal control; HMPV: human metapneumovirus; PIV: parainfluenzavirus; CMV: cytomegalovirus; PhHV: phocine

398 herpesvirus; HCoV: human coronavirus; HSV: herpes simplex virus

399

400 **Supplementary table 2: Ct values of pathogens detected by the respiratory panel in wastewater samples**  
 401 (Aquafin, Leuven) at different timepoints.

|          | Influenza A | Influenza B | RSV | HMPV | PIV-1 | PIV-2 | PIV-3 | PIV-4 | Adv | HBov | EV/RV | EV-D68 | HPeV | SARS-CoV | MERS-CoV | HCoV-NL63 | HCoV-229E | HCoV-OC43 | HCoV-HKU-1 | HSV-1 | HSV-2 | Cytomegalovirus | PMMoV |
|----------|-------------|-------------|-----|------|-------|-------|-------|-------|-----|------|-------|--------|------|----------|----------|-----------|-----------|-----------|------------|-------|-------|-----------------|-------|
| 6/12/20  |             |             |     |      |       |       |       |       | 27  | 30   | 29    |        | 32   |          |          |           |           |           |            |       |       |                 | 23    |
| 5/01/21  |             |             |     |      |       |       |       |       | 30  | 31   | 31    |        | 35   |          |          |           |           | 36        |            |       |       |                 | 24    |
| 11/01/21 |             |             |     |      |       |       |       |       | 28  | 32   | 29    |        | 34   |          |          |           |           |           |            |       |       |                 | 23    |
| 18/01/21 |             |             |     |      |       |       |       |       | 30  | 33   | 31    |        | 35   |          |          |           |           | 36        |            |       |       |                 | 24    |
| 1/02/21  |             |             |     |      |       |       |       |       | 33  | 33   | 31    |        | 36   |          |          |           |           |           |            |       |       |                 | 25    |
| 8/02/21  |             |             |     |      |       |       | 36    |       | 30  | 31   | 29    |        | 35   |          |          |           |           |           |            |       |       |                 | 24    |
| 22/02/21 |             |             |     |      |       |       | 34    |       | 26  | 31   | 30    |        | 34   |          |          | 37        |           | 36        |            |       |       |                 | 23    |
| 24/02/21 |             |             |     |      |       |       | 36    |       | 28  | 30   | 30    |        | 34   |          |          |           | 36        | 35        |            |       |       |                 | 25    |
| 8/03/21  |             |             | 39  |      |       |       | 32    |       | 30  | 29   | 30    |        | 34   |          |          |           | 38        | 36        |            |       |       |                 | 23    |
| 21/03/21 |             |             | 39  |      |       |       | 33    |       | 27  | 31   | 30    |        | 33   |          |          |           |           | 35        |            |       |       |                 | 23    |
| 31/03/21 |             |             | 36  |      |       |       | 34    | 44    | 27  | 32   | 30    |        | 34   |          |          |           | 36        | 33        |            |       |       |                 | 23    |
| 12/04/21 |             |             | 39  |      |       |       | 37    |       | 30  | 33   | 30    |        | 34   |          |          |           | 35        | 34        |            |       |       |                 | 25    |
| 3/05/21  |             |             | 37  |      |       |       | 37    |       | 29  | 31   | 31    |        | 36   |          |          |           |           | 34        |            |       |       |                 | 24    |
| 10/05/21 |             |             |     |      |       |       |       |       | 31  | 31   | 29    |        | 33   |          |          |           | 38        | 37        |            |       |       |                 | 26    |
| 19/05/21 |             |             | 37  |      |       |       |       |       | 29  | 32   | 28    |        | 35   |          |          |           |           | 34        |            |       |       |                 | 24    |
| 26/05/21 |             |             | 39  |      |       |       |       |       | 30  | 34   | 29    |        | 35   |          |          |           |           | 32        |            |       |       |                 | 24    |
| 31/05/21 |             |             | 39  |      |       |       |       |       | 29  | 31   | 29    |        | 33   |          |          |           | 38        | 34        |            |       |       |                 | 23    |
| 7/06/21  |             |             | 38  |      |       |       |       | 38    | 31  | 31   | 29    |        | 34   |          |          |           | 37        | 35        |            |       |       |                 | 24    |
| 5/07/21  |             |             |     |      |       |       | 38    |       | 31  | 32   | 32    |        | 35   |          |          |           |           |           |            |       |       |                 | 24    |
| 12/07/21 |             |             |     | 40   |       |       |       | 37    | 30  | 31   | 29    |        | 34   |          |          |           |           | 34        |            |       |       |                 | 23    |
| 19/07/21 |             |             |     |      |       |       |       |       | 32  | 35   | 34    |        | 38   |          |          |           |           | 37        |            |       |       |                 | 24    |
| 26/07/21 |             |             |     |      |       |       |       |       | 28  | 36   | 32    |        | 37   |          |          |           |           | 35        |            |       |       |                 | 25    |
| 2/08/21  |             |             |     |      |       |       | 37    | 38    | 25  | 35   | 31    |        | 36   |          |          |           |           | 37        |            |       |       |                 | 25    |
| 10/08/21 |             |             | 40  |      |       |       | 44    | 39    | 27  | 33   | 31    |        | 35   |          |          |           | 37        | 35        |            |       |       |                 | 24    |
| 16/08/21 |             |             |     |      |       |       | 37    | 37    | 23  | 31   | 29    |        | 34   |          |          |           |           | 36        |            |       |       |                 | 23    |
| 23/08/21 |             |             |     |      |       |       |       | 25    | 32  | 30   |       |        | 37   |          |          |           | 37        |           |            |       |       |                 | 24    |
| 30/08/21 |             |             | 39  |      |       |       | 36    | 38    | 26  | 34   | 29    |        | 33   |          |          |           | 35        | 35        |            |       |       |                 | 23    |
| 8/09/21  |             |             | 36  |      |       |       | 36    | 37    | 22  | 32   | 27    | 44     | 32   |          |          |           |           | 34        |            |       |       |                 | 23    |
| 15/09/21 |             |             |     |      |       |       |       | 38    | 25  | 33   | 28    | 37     | 33   |          |          |           | 37        | 34        |            |       |       |                 | 25    |
| 20/09/21 |             |             |     |      |       |       | 37    | 37    | 22  | 31   | 26    | 37     | 32   |          |          |           | 37        | 34        |            |       |       |                 | 23    |
| 27/09/21 |             |             |     | 40   |       |       | 36    | 37    | 23  | 32   | 26    | 36     | 31   | 36       |          |           |           | 32        |            |       |       |                 | 23    |
| 4/10/21  | 40          |             |     |      |       | 39    | 37    | 36    | 23  | 31   | 28    | 36     | 33   | 36       |          |           |           | 34        | 32         |       |       |                 | 24    |
| 13/10/21 |             |             | 36  | 40   |       |       | 36    | 35    | 22  | 29   | 27    | 35     | 33   |          |          |           | 35        | 30        |            |       |       | 35              | 23    |
| 20/10/21 |             |             | 36  |      |       | 39    | 36    | 36    | 23  | 31   | 26    | 35     | 33   | 37       |          |           | 36        | 32        |            | 35    |       |                 | 24    |
| 25/10/21 |             |             | 36  | 39   |       | 38    | 35    | 35    | 22  | 29   | 26    | 34     | 32   |          |          |           | 34        | 31        |            |       |       |                 | 24    |
| 8/11/21  |             |             | 36  | 39   |       | 38    | 34    | 35    | 22  | 30   | 27    | 35     | 32   | 35       |          |           | 33        | 32        |            |       |       |                 | 23    |
| 15/11/21 |             |             | 36  | 37   |       |       | 36    | 35    | 23  | 30   | 27    | 36     | 33   | 35       |          |           | 34        | 32        |            |       |       |                 | 24    |
| 22/11/21 |             |             | 35  |      |       | 36    | 34    | 37    | 23  | 30   | 27    | 37     | 33   | 34       |          |           | 33        | 31        |            |       |       |                 | 23    |
| 29/11/21 |             |             | 34  | 39   |       |       | 34    | 39    | 20  | 28   | 27    | 37     | 33   |          |          |           | 32        | 31        | 36         |       |       |                 | 24    |
| 6/12/21  |             |             | 34  |      |       | 38    | 34    | 38    | 21  | 29   | 27    | 38     | 33   |          |          |           | 34        | 33        | 34         |       |       |                 | 22    |
| 13/12/21 |             |             | 37  | 40   |       |       | 36    |       | 22  | 30   | 27    |        | 33   | 34       |          |           | 31        | 33        | 39         |       |       |                 | 22    |
| 20/12/21 |             |             | 38  | 39   |       |       | 37    |       | 22  | 30   | 27    |        | 34   | 36       |          |           | 33        | 32        | 34         |       |       |                 | 23    |
| 27/12/21 |             |             | 36  |      |       |       | 36    | 38    | 21  | 29   | 27    |        | 33   | 36       |          |           | 32        | 33        | 34         |       |       |                 | 23    |
| 3/01/22  |             |             |     |      |       | 41    |       |       | 23  | 31   | F     | 39     | 35   | 36       |          |           | 33        | 32        | 34         |       |       |                 | 24    |
| 10/01/22 |             |             |     |      |       |       | 37    |       | 22  | 31   | 28    |        | 36   | 35       |          |           | 33        | 34        | 33         |       |       |                 | 24    |

